Evaluation of Mycobacterium tuberculosis specific antigen-stimulated CD27-CD38+IFN-γ+CD4+ T cells for discrimination of active tuberculosis
- PMID: 36457066
- PMCID: PMC9714055
- DOI: 10.1186/s12879-022-07895-1
Evaluation of Mycobacterium tuberculosis specific antigen-stimulated CD27-CD38+IFN-γ+CD4+ T cells for discrimination of active tuberculosis
Abstract
Background: Active tuberculosis (ATB) originates from primary Mycobacterium tuberculosis (MTB) infection or reactivation of latent tuberculosis. Besides bacteriological examination, MTB-reactive immunocytes detection can be an alternative testing for discrimination of active tuberculosis. The purpose of this study is to investigate the accuracy of peripheral blood CD27-CD38+IFN-γ+CD4+T cells in ATB diagnosis.
Methods: This prospective diagnostic accuracy study was conducted at Shanghai Pulmonary Hospital between January 2019 and December 2021. Patients with ATB, non-tuberculosis mycobacterium infection (NTM), latent tuberculosis infection (LTBI), other respiratory diseases (OD), and healthy individuals (HC) were enrolled. The accuracy of CD27-CD38+IFN-γ+CD4+/CD4+ and other phenotypic markers for ATB diagnosis was assessed.
Results: A total of 376 patients (237 ATB, 38 LTBI, 8 NTM, 50 OD, and 43 HC) were enrolled. The ratios of CD4+IFN-γ+CD27- and CD4+IFN-γ+CD27-CD38+ profiles in CD4+IFN-γ+ cells and the ratios of CD4+IFN-γ+CD38+, CD4+IFN-γ+CD27-, and CD4+IFN-γ+CD38+CD27- profiles in CD4+ cells in the ATB group were significantly higher than in the other groups. The area under the curve (AUC) of CD27-CD38+IFN-γ+CD4+/CD4+ for the diagnosis of ATB was the highest, with a value of 0.890. With the optimal cutoff value of 1.34 × 10-4, the sensitivity and specificity of CD27-CD38+IFN-γ+CD4+/CD4+ for ATB diagnosis was 0.869 and 0.849, respectively.
Conclusion: CD27-CD38+IFN-γ+CD4+/CD4+ might be a potential biomarker for active tuberculosis diagnosis.
Keywords: Biomarker; CD27; CD38; Diagnosis; Flow cytometry; IFN−γ; Tuberculosis.
© 2022. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures





Similar articles
-
Activation Phenotype of Mycobacterium tuberculosis-Specific CD4+ T Cells Promoting the Discrimination Between Active Tuberculosis and Latent Tuberculosis Infection.Front Immunol. 2021 Aug 26;12:721013. doi: 10.3389/fimmu.2021.721013. eCollection 2021. Front Immunol. 2021. PMID: 34512645 Free PMC article.
-
Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response.J Clin Invest. 2015 May;125(5):1827-38. doi: 10.1172/JCI77990. Epub 2015 Mar 30. J Clin Invest. 2015. PMID: 25822019 Free PMC article. Clinical Trial.
-
Study of CD27, CD38, HLA-DR and Ki-67 immune profiles for the characterization of active tuberculosis, latent infection and end of treatment.Front Microbiol. 2022 Jul 22;13:885312. doi: 10.3389/fmicb.2022.885312. eCollection 2022. Front Microbiol. 2022. PMID: 35935194 Free PMC article.
-
[Evolution of IGRA researches].Kekkaku. 2008 Sep;83(9):641-52. Kekkaku. 2008. PMID: 18979999 Review. Japanese.
-
A Systematic Review on Novel Mycobacterium tuberculosis Antigens and Their Discriminatory Potential for the Diagnosis of Latent and Active Tuberculosis.Front Immunol. 2018 Nov 9;9:2476. doi: 10.3389/fimmu.2018.02476. eCollection 2018. Front Immunol. 2018. PMID: 30473692 Free PMC article.
Cited by
-
Differentiating Latent Tuberculosis from Active Tuberculosis Through Activation Phenotypes and Chemokine Markers HLA-DR, CD38, MCP-1, and RANTES: A Systematic Review and Meta-Analysis.Biomark Insights. 2025 Jan 8;20:11772719241312776. doi: 10.1177/11772719241312776. eCollection 2025. Biomark Insights. 2025. PMID: 39802700 Free PMC article.
-
Active tuberculosis patients have high systemic IgG levels and B-cell fingerprinting, characterized by a reduced capacity to produce IFN-γ or IL-10 as a response to M.tb antigens.Front Immunol. 2023 Oct 26;14:1263458. doi: 10.3389/fimmu.2023.1263458. eCollection 2023. Front Immunol. 2023. PMID: 38022616 Free PMC article.
-
A comprehensive approach to developing a multi-epitope vaccine against Mycobacterium tuberculosis: from in silico design to in vitro immunization evaluation.Front Immunol. 2023 Nov 2;14:1280299. doi: 10.3389/fimmu.2023.1280299. eCollection 2023. Front Immunol. 2023. PMID: 38022558 Free PMC article.
References
-
- World Health Organization. Global tuberculosis report 2018. World Health Organization. WHO/CDS/TB; 2018.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials